Upon intracranial or intravenous administration, Bcl2L12-SNAs could cross the blood-brain barrier (BBB), penetrate the glioma, and promote apoptosis of glioma cells by enhancing caspase and p53 activities. The gene discussed is TP53; the disease is central nervous system cancer.